March 4 (Reuters) – U.S. health regulators on Wednesday
swiftly approved a Bristol-Myers Squibb Co drug that
helps the immune system fight the most common form of lung
cancer, sending the company’s shares up more than 5 percent to a
The eagerly anticipated Food and Drug Administration
approval of the drug known as Opdivo came only about three
months after Bristol provided trial results showing that the
medicine extended survival in non-small cell lung cancer
(NSCLC), one of the biggest markets in oncology. The decision
also came more than three months ahead of an expected action
date by the agency.
By Bill Berkrot
(Reuters) – Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’ Sovaldi, according to data from a study presented on Thursday.
The results could help put Bristol’s hepatitis C program back on track in the United States, following a setback last year.
Feb 26 (Reuters) – Ninety-seven percent of hepatitis C
patients also infected with HIV were cured of the
liver-destroying virus after 12 weeks of treatment with
Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’
Sovaldi, according to data from a study presented on
The results could help put Bristol’s hepatitis C program
back on track in the United States, following a setback last
By Bill Berkrot
(Reuters) – Sanofi’s new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult.
Toujeo is a more potent follow-up to the French drugmaker’s top-selling Lantus insulin product, which accounts for a fifth of group sales and is due to go off U.S. patent this year.
Feb 25 (Reuters) – U.S. health regulators on Wednesday
approved Sanofi’s diabetes drug Toujeo, a more potent
follow-up to the French drugmaker’s top-selling insulin product
The Food and Drug Administration approved the once daily,
long-acting basal insulin to treat adults with both type 1 and
the far more prevalent type 2 diabetes.
NEW YORK (Reuters) – Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.
The company, which has come under intense criticism in the United States for the high price of its treatments for the liver destroying virus, is negotiating price cuts in Europe in exchange for patient volume promises.
By Bill Berkrot and Joseph Menn
(Reuters) – Health insurer Anthem Inc on Friday warned U.S. customers about an email scam targeting former and current members whose personal information was suspected to have been breached in a massive cyber attack.
The No. 2 U.S. health insurer said on Wednesday that hackers breached its computer system containing data on up to 80 million people.
NEW YORK, Feb 5 (Reuters) – Pfizer Inc’s $15 billion deal to
buy Hospira Inc will allow the largest U.S. drugmaker to benefit
from specialty generic medicines that are commanding far higher
prices than traditional off-patent pills, industry investors and
High demand for many of its injectable sterile drugs,
including outright shortages in some cases, has allowed Hospira
to increase prices in recent years.
Jan 30 (Reuters) – AbbVie Inc’s chief executive
said on Friday the company’s new hepatitis C treatment Viekira
Pak has the potential to capture a “meaningful share” of the
U.S. market, where it is competing against Gilead Sciences
AbbVie CEO Richard Gonzalez told investors the company
expects an annualized sales run rate of more than $3 billion by
the end of 2015, which could grow beyond that as more countries
begin using Viekira Pak, which is a combination of several
Jan 29 (Reuters) – Scientific instruments maker PerkinElmer
Inc on Thursday reported better-than-expected fourth
quarter revenue and profit, helped by strong demand for its
newborn screening tests in developing markets.
The company forecast 2015 adjusted earnings of $2.58 to 2.64
per share, assuming the stronger U.S. dollar will reduce profit
by about 15 cents. Analysts’ estimates are already at the high
end of the range at $2.64 per share.